Electronic sepsis screening, a procedure that’s taking the healthcare industry by storm, has shown a remarkable effect on reducing 90-day in-hospital mortality rates among ward patients. This updated approach was discussed in a study published online on December 10 in the Journal of the American Medical Association. The study’s release coincided with the anticipated Critical Care Reviews Down Under meeting in Melbourne, Australia between December 10 and 11.
The study was orchestrated under the watchful eye of Dr. Yaseen M. Arabi from King Abdulaziz Medical City in Riyadh, Saudi Arabia, alongside a team of competent researchers. They focused on the comparison between electronic sepsis screening and a lack thereof, and its impact on the mortality rates of hospitalized patients. The research carried out a comprehensive analysis of data from a voluminous number of 60,055 ward patients across five hospitals. This included a controlled group of 29,442 who referred to the electronic screening method, matched against a check group of 30,613 with no screening mechanisms. To ensure a balanced approach, 45 wards or clusters were randomly allocated nine sequences, five wards each, to implement the sepsis screening at a controlled, two-month period.
The carefully delineated study unearthed notable results, with 14.6% alerts in the electronic screening group, compared to a slightly increased 17.6% in the non-screening group. Significantly, patients resorting to electronic screening had a higher likelihood of undergoing serum lactate testing (an adjusted relative risk [aRR] of 1.30) and receiving intravenous fluid orders (aRR of 2.17) within 12 hours of the alert. Crucially, the electronic screening method led to a reduced 90-day in-hospital mortality rate (aRR of 0.85), offering a critical insight into its efficacy.
Despite this success, the study also highlighted some areas of concern. The screening method inadvertently resulted in increased code blue activation, a rise in incident kidney replacement therapy, and a greater occurrence of the Clostridioides difficile bacterium. However, the screening’s benefits cannot be underestimated, as it simultaneously reduced the need for intense vasopressor therapy and diminished the presence of multidrug-resistant organisms.
The researchers concluded that despite these obstacles, the intervention method remained continuous, reliable, sustainable, and unbiased with low operational costs. It should be noted, however, that one author reported a pending patent that may introduce further advancements in this method. The detailed study information can be found in the provided link.